Response Scientific, Inc.™ (RSI) is a Life Sciences Biotechnology Corporation. Our focus is on improving patient treatments in disease states related to insulin resistance. These include Type 1 and Type 2 Diabetes, Pre-Diabetes, Polycystic Ovarian Syndrome (PCOS), Alzheimer’s disease, and the various complications associated with them.
Our goal is to develop products, both prescription and over-the-counter, which improve the lives of people suffering from these related maladies.
Our Pharmaceuticals division is primarily concerned with reestablishing insulin receptor cell sensitivity so that insulin is processed more efficiently and returns to full functionality.
Our Consumer Products division is focused on over-the-counter treatments that address the many complications associated with these disease states.
RSI/Pharmaceuticals Division is developing an investigational diabetes new drug technology, code-named INS2, that has presented the ability to reduce the amount of insulin required by type 1 and type 2 insulin dependent people to maintain target blood glucose by as much as fifty percent.
RSI/Consumer Products Division has developed solutions based on our research of the complications caused by Insulin Resistance and Diabetes. These include ground-breaking new natural products for the complications of Dry Skin (Feet) and safe Arthritis/Fibromyalgia Pain Relief.
